The Trial of Org 10172 of Acute Stroke Treatment pada Era Pandemi COVID-19

Abstract

Background and Objective: The Trial of Org 10172 of Acute Stroke Treatment (TOAST) classification was introduced to classify ischemic stroke based on potential etiological mechanisms. The purpose of this study was to assess the characteristics of acute ischemic stroke patients based on the TOAST classification during the COVID-19 pandemic era. Subject and Methods: This research was a descriptive cross-sectional study from the medical records of acute ischemic stroke patients who were treated in Neurology ward of Hasan Sadikin Hospital in 2021. Results: A total of 136 acute ischemic stroke patients were involved in this study. Large-artery atherosclerosis (LAA) was the most common stroke subtype (30.1%) and hypertension is the most common risk factor (97%). The risk factors for hypercoagulation were found to be 79% in the Undetermined etiology classification and 100% in the Other etiology classification. Conclusion: In the COVID-19 pandemic era, hypercoagulation was found as the dominant risk factor in the Undetermined etiology and Other etiology classifications. The coagulopathy mechanism in COVID-19 could increase the risk of stroke in affected person who have conventional stroke risk factors.